• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Retina >INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
【24h】

INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

机译：预先准备好的与新鲜制备的葡萄膜内贝伐珠单抗治疗持续性眼压过高相关的血管性黄斑变性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose:To compare the incidence of sustained ocular hypertension (OHT) after intravitreal injections of prepackaged versus freshly prepared bevacizumab monotherapy for the treatment of neovascular age-related macular degeneration.Methods:Charts of 1,216 patients with neovascular age-related macular degeneration receiving intravitreal bevacizumab monotherapy at 2 retina practices using different preparations of bevacizumab between January 1, 2009, and December 31, 2011, were reviewed. Primary outcome was incidence of sustained OHT, defined as intraocular pressure >25 mmHg with an increase 6 from baseline on 2 consecutive visits or requiring treatment.Results:A total of 6,479 injections in 740 eyes of 634 patients were included and 14 eyes (0.81% incidence per eye-year) developed sustained OHT. For eyes receiving prepackaged bevacizumab, 10 of 339 eyes (1.39% incidence per eye-year) developed sustained OHT compared with 4 of 401 eyes (0.39% incidence per eye-year) receiving freshly prepared bevacizumab, giving an incidence rate ratio of 3.55 (95% confidence interval, 0.93-13.49; P = 0.063). All eyes that developed sustained OHT achieved intraocular pressure control with observation or topical therapy alone.Conclusion:Incidence of sustained OHT after intravitreal bevacizumab is low. We found a trend toward higher rates of sustained OHT with prepackaged bevacizumab although this difference was not statistically or clinically significant.
机译：目的：比较玻璃体腔内注射预先包装的贝伐单抗与新鲜制备的贝伐单抗单药治疗新血管性年龄相关性黄斑变性后持续性高眼压（OHT）的发生率。方法：1,216例玻璃体腔注射贝伐单抗的新血管性年龄相关性黄斑变性患者回顾了2009年1月1日至2011年12月31日使用2种不同贝伐单抗制剂在视网膜上进行的单药治疗。主要结局为持续性OHT发生率，其定义为眼压> 25 mmHg，连续2次就诊或需要治疗时比基线增加6倍。结果：634例患者的740眼共注入6479眼，其中14眼（0.81％每眼年发生率）发展为持续性OHT。对于接受预包装贝伐单抗的眼，持续性OHT占339眼中的10眼（每眼年发生率1.39％），与之相比，接受新鲜贝伐单抗的401眼中有4眼（每眼年发生率0.39％）发展为持续性OHT，发生率为3.55（ 95％置信区间0.93-13.49; P = 0.063）。所有发展为持续性OHT的眼睛仅通过观察或局部治疗即可达到眼压控制。我们发现，预包装贝伐单抗持续OHT发生率呈上升趋势，尽管这种差异在统计学或临床上均无统计学意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号